MARKET

LUMO

LUMO

Lumos Pharma Inc
NASDAQ
2.620
+0.080
+3.15%
Closed 18:53 05/20 EDT
OPEN
2.650
PREV CLOSE
2.540
HIGH
2.695
LOW
2.515
VOLUME
51.67K
TURNOVER
0
52 WEEK HIGH
4.550
52 WEEK LOW
2.010
MARKET CAP
21.27M
P/E (TTM)
-0.5707
1D
5D
1M
3M
1Y
5Y
Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024
Barchart · 22h ago
Weekly Report: what happened at LUMO last week (0513-0517)?
Weekly Report · 1d ago
Lumos Pharma, Inc. Form 10-Q for the Quarterly Period Ended March 31, 2024
Press release · 5d ago
Lumos Pharma GAAP EPS of -$1.29 misses by $0.11, revenue of $0.17M misses by $0.13M
Lumos Pharma's Q1 GAAP EPS of -$ misses by $ and revenue of $ misses by $. The company ended the quarter with cash, cash equivalents and short-term investments of $ million. Lumos Pharma is expected to continue operations through Q3 2024.
Seeking Alpha · 6d ago
LUMO Stock Earnings: Lumos Pharma Misses EPS, Misses Revenue for Q1 2024
Lumos Pharma reported earnings per share of -$ for the first quarter of 2024. The company reported revenue of $165,000. This was 45% worse than the analyst estimate for revenue. Lumos Pharma also reported results for the fourth quarter of 2015. The stock is down 2.7% in the last day.
Investorplace · 6d ago
TFF Pharmaceuticals, Inc. (TFFP) Reports Q1 Loss, Tops Revenue Estimates
NASDAQ · 6d ago
*Lumos Pharma: Cash on Hand Is Expected to Support Ops Through 3Q
Dow Jones · 6d ago
*Lumos Pharma Expects to Initiate Phase 3 Trial of LUM-201 in 4Q, Subject to FDA Approval >LUMO
Dow Jones · 6d ago
More
About LUMO
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing its clinical program and focused on identifying, acquiring, developing, and commercializing products and new therapies for people with rare diseases. Its pipeline is focused on the development of an orally administered small molecule, LUM-201, which is a growth hormone (GH) secretagogue, also called ibutamoren, for rare endocrine disorders that require injectable recombinant human growth hormone (rhGH). LUM-201 is a tablet formulation that is intended to be administered once daily. LUM-201 stimulates GH via the GH secretagogue receptor (GHSR1a), also known as the ghrelin receptor, and also suppresses the release of somatostatin, thus providing a differentiated mechanism of action to treat some rare endocrine disorders (involving a deficiency of GH) by increasing the amplitude of endogenous, pulsatile GH secretion. Lumos Pharma Sub, Inc. (Private Lumos) is its subsidiary.

Webull offers Lumos Pharma Inc stock information, including NASDAQ: LUMO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LUMO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LUMO stock methods without spending real money on the virtual paper trading platform.